1981Journal of Antimicrobial ChemotherapyRequires access

Comparative in-vitro activity of ceftazidime (GR-20263) and other -lactamase stable cephalosporins against anaerobic bacteria

Anthony W. Chow, Karen H. Bartlett

Open publisher page 14 citations

Abstract

The in-vitro activity of ceftazidime was determined against 586 clinical isolates of anaerobic bacteria by an agar-dilution technique and compared with that of cefuroxime, moxalactam and cefoxitin. At 16 mg/l, only 60% of all isolates were inhibited by ceftazidime, compared to 79% by cefuroxime, 81% by moxalactam and 80% by cefoxitin. Ceftazidime was relatively inactive against Bacteroides fragilis group, Lactobacillus and Clostridium species other than Cl. perfringens. Peptococcus, Peptostreptococcus, Cl. perfringens, microaerophilic streptococci and Propionibacterium were readily inhibited. Moxalactam was the most active agent against Bact. fragilis group, while cefuroxime was the most active agent against Streptococcus and Lactobacillus.

About this research paper

What this paper is about

The in-vitro activity of ceftazidime was determined against 586 clinical isolates of anaerobic bacteria by an agar-dilution technique and compared with that of cefuroxime, moxalactam and cefoxitin. At 16 mg/l, only 60% of all isolates were inhibited by ceftazidime, compared to 79% by cefuroxime, 81% by moxalactam and 80% by cefoxitin. Ceftazidime was relatively inactive against Bacteroides fragilis group, Lactobacillus and Clostridium species other than Cl. perfringens. Peptococcus, Peptostreptococcus, Cl. perfringens, microaerophilic streptococci and Propionibacterium were readily inhibited. Moxalactam was the most active agent against Bact. fragilis group, while cefuroxime was the most active agent against Streptococcus and Lactobacillus.

Why it matters

OpenAlex reports 14 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

The in-vitro activity of ceftazidime was determined against 586 clinical isolates of anaerobic bacteria by an agar-dilution technique and compared with that of cefuroxime, moxalactam and cefoxitin. At 16 mg/l, only 60% of all isolates were inhibited by ceftazidime, compared to 79% by cefuroxime, 81% by moxalactam and 80% by cefoxitin. Ceftazidime was relatively inactive against Bacteroides fragilis group, Lactobacillus and Clostridium species other than Cl. perfringens. Peptococcus, Peptostreptococcus, Cl. perfringens, microaerophilic streptococci and Propionibacterium were readily inhibited. Moxalactam was the most active agent against Bact. fragilis group, while cefuroxime was the most active agent against Streptococcus and Lactobacillus.

Key concepts: Moxalactam, Cefoxitin, Bacteroides fragilis, Ceftazidime, Cefuroxime, Microbiology, Clostridium perfringens, Agar dilution

Related papers

Back to paper searchBrowse research topicsOriginal source
Comparative in-vitro activity of ceftazidime (GR-20263) and other -lactamase stable cephalosporins against anaerobic bacteria — Research Paper | ScholarLens